Novel insights in molecular mechanisms of CLL

Current Pharmaceutical Design

Volumn 18, Issue 23, 2012, Pages 3363-3372

  Zanesi, Nicola ^a   Balatti, Veronica ^a   Bottoni, Arianna ^a   Croce, Carlo M ^a   Pekarsky, Yuri ^a  

^a THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

CLL; DLEU7; Mir 15 16; Mir 29; NOTCH1; TCL1

Indexed keywords

B LYMPHOCYTE RECEPTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MICRORNA 15A; MICRORNA 16; NOTCH1 RECEPTOR; PROTEIN C FOS; PROTEIN C JUN; PROTEIN KINASE B; TRANSCRIPTION FACTOR AP 1; TRANSCRIPTION FACTOR NFAT; TUMOR NECROSIS FACTOR; TUMOR SUPPRESSOR PROTEIN;

ARTICLE; CANCER PROGNOSIS; CARCINOGENESIS; CELL MIGRATION; CHROMOSOME REARRANGEMENT; CHRONIC LYMPHATIC LEUKEMIA; CYTOGENETICS; DNA METHYLATION; DNA SEQUENCE; DOWN REGULATION; ENZYME PHOSPHORYLATION; GENE DELETION; GENE MAPPING; GENE MUTATION; HUMAN; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; PROLYMPHOCYTIC LEUKEMIA; PROTEIN BINDING; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; T CELL LEUKEMIA;

ANIMALS; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 13; DISEASE MODELS, ANIMAL; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MICE; PROTO-ONCOGENE PROTEINS;

EID: 84863529042     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161212801227104     Document Type: Article

References (106)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics 2010. CA Cancer J Clin 2010; 60: 277-300.
2. Bullrich F, Croce C. Molecular Biology of Chronic Lymphocytic Leukemia. Chronic Lymphocytic Leukemias, Second Edition, Revised and Expanded, Bruce Cheson, Ed. Marcel Dekker, Inc. New York 2001: 9-32.
3. Chiorazzi N. Cell proliferation and death: forgotten features of chronic lymphocytic leukemia B cells. Best Pract Res Clin Haematol 2007; 20: 399-413.
4. Messmer BT, Messmer D, Allen SL, et al. In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cells. J Clin Invest 2005; 115: 755-64.
5. Sieklucka M, Pozarowski P, Bojarska-Junak A, Hus I, Dmoszynska A, Rolinski J. Apoptosis in B-CLL: the relationship between higher ex vivo spontaneous apoptosis before treatment in III-IV Rai stage patients and poor outcome. Oncol Rep 2008; 19: 1611-20.
6. Rassenti LZ, Huynh L, Toy TL, et al. ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N Engl J Med 2004; 351: 893-901.
7. Orchard JA, Ibbotson RE, Davis Z, et al. ZAP-70 expression and prognosis in chronic lymphocytic leukaemia. Lancet 2004; 363: 105-11.
8. Chiorazzi N, Rai KR, Ferrarini M. Chronic lymphocytic leukemia. N Engl J Med 2005; 352: 804-15.
9. Dohner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000; 343: 1910-6.
10. Virgilio L, Narducci MG, Isobe M, et al. Identification of the TCL1 gene involved in T-cell malignancies. Proc Natl Acad Sci USA 1994; 91: 12530-4.
11. Kingreen D, Siegert W. Chrinic lymphatic leukemias of T and NK cell type. Leukemia 2000; 11: s46-s49.
12. Catovsky D. Chronic lymphoproliferative disorders. Curr Opin Oncol 1995; 7: 3-11.
13. Croce CM. Role of chromosome translocations in human neoplasia. Cell 1987; 49: 155-6.
14. Croce CM, Isobe M, Palumbo A, et al. Gene for alpha-chain of human T-cell receptor: location on chromosome 14 region involved in T-cell neoplasms. Science 1985; 227: 1044-7.
15. Russo G, Isobe M, Gatti R, et al. Molecular analysis of a t(14;14) translocation in leukemic T-cells of an ataxia telangiectasia patient. Proc Natl Acad Sci USA 1989; 86: 602-6.
16. Virgilio L, Isobe M, Narducci MG, et al. Chromosome walking on the TCL1 locus involved in T-cell neoplasia. Proc Natl Acad Sci USA 1993; 90: 9275-9.
17. Pekarsky Y, Hallas C, Isobe M, Russo G, Croce CM. Abnormalities at 14q32.1 in T cell malignancies involve two oncogenes. Proc Natl Acad Sci USA 1999; 96: 2949-51.
18. Hallas C, Pekarsky Y, Itoyama T, et al. Genomic analysis of human and mouse TCL1 loci reveals a complex of tightly clustered genes. Proc Natl Acad Sci USA 1999; 96: 14418-23.
19. Stern MH, Soulier J, Rosenzwajg M, et al. MTCP-1: a novel gene on the human chromosome Xq28 translocated to the T cell receptor alpha/delta locus in mature T cell proliferations. Oncogene 1993; 8: 2475-83.
20. Takizawa J, Suzuki R, Kuroda H, et al. Expression of the TCL1 gene at 14q32 in B-cell malignancies but not in adult T-cell leukemia. Jpn J Cancer Res 1998; 89: 712-8.
21. Narducci MG, Pescarmona E, Lazzeri C, Signoretti S, Lavinia AM, Remotti D, Scala E, Baroni CD, Stoppacciaro A, Croce CM, Russo G. Regulation of TCL1 expression in B- and T-cell lymphomas and reactive lymphoid tissues. Cancer Res 2000; 60: 2095-100.
22. Bichi R, Shinton SA, Martin ES, et al. Human chronic lymphocytic leukemia modeled in mouse by targeted TCL1 expression. Proc Natl Acad Sci USA 2002; 99: 6955-60.
23. Pekarsky Y, Calin GA, Aqeilan R. Chronic lymphocytic leukemia: molecular genetics and animal models. Curr Top Microbiol Immunol 2005; 294: 51-70.
24. Herling M, Patel KA, Khalili J, et al. TCL1 shows a regulated expression pattern in chronic lymphocytic leukemia that correlates with molecular subtypes and proliferative state. Leukemia 2006; 20: 280-5.
25. Pekarsky Y, Koval A, Hallas C, et al. Tcl1 enhances Akt kinase activity and mediates its nuclear translocation. Proc Natl Acad Sci USA 2000; 97: 3028-33.
26. Laine J, Kunstle G, Obata T, Sha M, Noguchi M. The protooncogene TCL1 is an Akt kinase coactivator. Mol Cell 2000; 6: 395-407.
27. Staal SP, Hartley JW, Rowe WP. Isolation of transforming murine leukemia viruses from mice with a high incidence of spontaneous lymphoma. Proc Natl Acad Sci USA 1977; 74: 3065-7.
28. Chan TO, Rittenhouse SE, Tsichlis PN. AKT/PKB and other D3 phosphoinositide-regulated kinases: kinase activation by phosphoinositide- dependent phosphorylation. Annu Rev Biochem 1999; 68: 965-1014.
29. Ahmed NN, Grimes HL, Bellacosa A, Chan TO, Tsichlis PN. Transduction of interleukin-2 antiapoptotic and proliferative signals via Akt protein kinase. Proc Natl Acad Sci USA 1997; 94: 3627-32.
30. Pekarsky Y, Hallas C, Croce CM. Molecular basis of mature T-cell leukemia. Jama 2001; 286: 2308-14.
31. Pekarsky Y, Hallas C, Palamarchuk A, et al. Akt phosphorylates and regulates the orphan nuclear receptor Nur77. Proc Natl Acad Sci USA 2001; 98: 3690-4.
32. Pekarsky Y, Zanesi N, Aqeilan R, Croce CM. Tcl1 as a model for lymphomagenesis. Hematol Oncol Clin North Am 2004; 18: 863-79, ix.
33. Cheng LE, Chan FK, Cado D, Winoto A. Functional redundancy of the Nur77 and Nor-1 orphan steroid receptors in T-cell apoptosis. Embo J 1997; 16: 1865-75.
34. Palamarchuk A, Efanov A, Maximov V, Aqeilan RI, Croce CM, Pekarsky Y. Akt phosphorylates Tal1 oncoprotein and inhibits its repressor activity. Cancer Res 2005; 65: 4515-9.
35. Pekarsky Y, Santanam U, Cimmino A, et al. Tcl1 expression in chronic lymphocytic leukemia is regulated by miR-29 and miR- 181. Cancer Res 2006; 66: 11590-3.
36. Calin GA, Ferracin M, Cimmino A, et al. A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med 2005; 353: 1793-801.
37. Calin GA, Liu CG, Sevignani C, et al. MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias. Proc Natl Acad Sci USA 2004; 101: 11755-60.
38. Ramkissoon SH, Mainwaring LA, Ogasawara Y, et al. Hematopoietic- specific microRNA expression in human cells. Leuk Res 2005; 30: 643-647.
39. Malstrom S, Tili E, Kappes D, Ceci JD, Tsichlis PN. Tumor induction by an Lck-MyrAkt transgene is delayed by mechanisms controlling the size of the thymus. Proc Natl Acad Sci USA 2001; 98: 14967-72.
40. Suzuki A, Kaisho T, Ohishi M, et al. Critical roles of Pten in B cell homeostasis and immunoglobulin class switch recombination. J Exp Med 2003; 197: 657-67.
41. Pekarsky Y, Palamarchuk A, Maximov V, et al. Tcl1 functions as a transcriptional regulator and is directly involved in the pathogenesis of CLL. Proc Natl Acad Sci USA 2008; 105: 19643-8.
42. Pekarsky Y, Zanesi N, Aqeilan RI, Croce CM. Animal models for chronic lymphocytic leukemia. J Cell Biochem 2007; 100: 1109-18.
43. Planelles L, Carvalho-Pinto CE, Hardenberg G, et al. APRIL promotes B-1 cell-associated neoplasm. Cancer Cell 2004; 6: 399-408.
44. Ghosh AK, Varga J. The transcriptional coactivator and acetyltransferase p300 in fibroblast biology and fibrosis. J Cell Physiol 2007; 213: 663-71.
45. Hess J, Angel P, Schorpp-Kistner M. AP-1 subunits: quarrel and harmony among siblings. J Cell Sci 2004; 117: 5965-73.
46. Leppa S, Bohmann D. Diverse functions of JNK signaling and c- Jun in stress response and apoptosis. Oncogene 1999; 18: 6158-62.
47. Ameyar M, Wisniewska M, Weitzman JB. A role for AP-1 in apoptosis: the case for and against. Biochimie 2003; 85: 747-52.
48. Foletta VC, Segal DH, Cohen DR. Transcriptional regulation in the immune system: all roads lead to AP-1. J Leukoc Biol 1998; 63: 139-52.
49. Colotta F, Polentarutti N, Sironi M, Mantovani A. Expression and involvement of c-fos and c-jun protooncogenes in programmed cell death induced by growth factor deprivation in lymphoid cell lines. J Biol Chem 1992; 267: 18278-83.
50. Ott RG, Simma O, Kollmann K, et al. JunB is a gatekeeper for Blymphoid leukemia. Oncogene 2007; 26: 4863-71.
51. Bullrich F, Fujii H, Calin G, et al. Characterization of the 13q14 tumor suppressor locus in CLL: identification of ALT1, an alternative splice variant of the LEU2 gene. Cancer Res 2001; 61: 6640-8.
52. Migliazza A, Bosch F, Komatsu H, et al. Nucleotide sequence, transcription map, and mutation analysis of the 13q14 chromosomal region deleted in B-cell chronic lymphocytic leukemia. Blood 2001; 97: 2098-104.
53. Rondeau G, Moreau I, Bezieau S, et al. Comprehensive analysis of a large genomic sequence at the putative B-cell chronic lymphocytic leukaemia (B-CLL) tumour suppresser gene locus. Mutat Res 2001; 458: 55-70.
54. Mertens D, Wolf S, Schroeter P, et al. Down-regulation of candidate tumor suppressor genes within chromosome band 13q14.3 is independent of the DNA methylation pattern in B-cell chronic lymphocytic leukemia. Blood 2002; 99: 4116-21.
55. Calin GA, Dumitru CD, Shimizu M, et al. Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 2002; 99: 15524-9.
56. Wolf S, Mertens D, Schaffner C, et al. B-cell neoplasia associated gene with multiple splicing (BCMS): the candidate B-CLL gene on 13q14 comprises more than 560 kb covering all critical regions. Hum Mol Genet 2001; 10: 1275-85.
57. Cimmino A, Calin GA, Fabbri M, et al. miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci USA 2005; 102: 13944-9.
58. Calin GA, Cimmino A, Fabbri M, et al. MiR-15a and miR-16-1 cluster functions in human leukemia. Proc Natl Acad Sci USA 2008; 105: 5166-71.
59. Fabbri M, Bottoni A, Shimizu M, et al. Association of a microRNA/ TP53 feedback circuitry with pathogenesis and outcome of B-cell chronic lymphocytic leukemia. Jama 2011; 305: 59-67.
60. Raveche ES, Salerno E, Scaglione BJ, et al. Abnormal microRNA- 16 locus with synteny to human 13q14 linked to CLL in NZB mice. Blood 2007; 109: 5079-86.
61. Ouillette P, Erba H, Kujawski L, Kaminski M, Shedden K, Malek SN. Integrated genomic profiling of chronic lymphocytic leukemia identifies subtypes of deletion 13q14. Cancer Res 2008; 68: 1012-21.
62. Hammarsund M, Corcoran MM, Wilson W, et al. Characterization of a novel B-CLL candidate gene--DLEU7--located in the 13q14 tumor suppressor locus. FEBS Lett 2004; 556: 75-80.
63. Palamarchuk A, Efanov A, Nazaryan N, et al. 13q14 deletions in CLL involve cooperating tumor suppressors. Blood 2010; 115: 3916-22.
64. Haiat S, Billard C, Quiney C, Ajchenbaum-Cymbalista F, Kolb JP. Role of BAFF and APRIL in human B-cell chronic lymphocytic leukaemia. Immunology 2006; 118: 281-92.
65. Mackay F, Schneider P, Rennert P, Browning J. BAFF AND APRIL: a tutorial on B cell survival. Annu Rev Immunol 2003; 21: 231-64.
66. Schuh K, Avots A, Tony HP, Serfling E, Kneitz C. Nuclear NFATp is a hallmark of unstimulated B cells from B-CLL patients. Leuk Lymphoma 1996; 23: 583-92.
67. Berland R, Wortis HH. An NFAT-dependent enhancer is necessary for anti-IgM-mediated induction of murine CD5 expression in primary splenic B cells. J Immunol 1998; 161: 277-85.
68. Fabbri G, Rasi S, Rossi D, et al. Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation. J Exp Med; 208: 1389-401.
69. Puente XS, Pinyol M, Quesada V, et al. Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature 2011; 475: 101-5.
70. Koch U, Radtke F. Notch in T-ALL: new players in a complex disease. Trends Immunol; 32: 434-42.
71. Aster JC, Blacklow SC, Pear WS. Notch signalling in T-cell lymphoblastic leukaemia/lymphoma and other haematological malignancies. J Pathol; 223: 262-73.
72. Weng AP, Ferrando AA, Lee W, et al. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science 2004; 306: 269-71.
73. Itoh M, Fu L, Tohda S. NF-kappaB activation induced by Notch ligand stimulation in acute myeloid leukemia cells. Oncol Rep 2009; 22: 631-4.
74. Espinosa L, Cathelin S, D'Altri T, et al. The Notch/Hes1 pathway sustains NF-kappaB activation through CYLD repression in T cell leukemia. Cancer Cell 2010; 18: 268-81.
75. Rosati E, Sabatini R, Rampino G, et al. Constitutively activated Notch signaling is involved in survival and apoptosis resistance of B-CLL cells. Blood 2009; 113: 856-65.
76. Zanesi N, Pekarsky Y, Trapasso F, Calin G, Croce C. MicroRNAs in mouse models of lymphoid malignancies. J Nucleic Acids Invest 2010; 1: 36-40.
77. Santanam U, Zanesi N, Efanov A, et al. Chronic lymphocytic leukemia modeled in mouse by targeted miR-29 expression. Proc Natl Acad Sci USA 2010; 107: 12210-12215.
78. Raveche ES. Possible immunoregulatory role for CD5 + B cells. Clin Immunol Immunopathol 1990; 56: 135-50.
79. Klein U, Lia M, Crespo M, et al. The DLEU2/miR-15a/16-1 cluster controls B cell proliferation and its deletion leads to chronic lymphocytic leukemia. Cancer Cell 2010; 17: 28-40.
80. Katsumata M, Siegel RM, Louie DC, et al. Differential effects of Bcl-2 on T and B cells in transgenic mice. Proc Natl Acad Sci USA 1992; 89: 11376-80.
81. Lee SY, Reichlin A, Santana A, Sokol KA, Nussenzweig MC, Choi Y. TRAF2 is essential for JNK but not NF-kappaB activation and regulates lymphocyte proliferation and survival. Immunity 1997; 7: 703-13.
82. Chung JY, Park YC, Ye H, Wu H. All TRAFs are not created equal: common and distinct molecular mechanisms of TRAFmediated signal transduction. J Cell Sci 2002; 115: 679-88.
83. Zapata JM, Krajewska M, Morse HC, 3rd, Choi Y, Reed JC. TNF receptor-associated factor (TRAF) domain and Bcl-2 cooperate to induce small B cell lymphoma/chronic lymphocytic leukemia in transgenic mice. Proc Natl Acad Sci USA 2004; 101: 16600-5.
84. Kantor AB, Herzenberg LA. Origin of murine B cell lineages. Annu Rev Immunol 1993; 11: 501-38.
85. Pekarsky Y, Zanesi N, Croce CM. Molecular basis of CLL. Semin Cancer Biol 2010; 20: 370-6.
86. Hoyer KK, French SW, Turner DE, et al. Dysregulated TCL1 promotes multiple classes of mature B cell lymphoma. Proc Natl Acad Sci USA 2002; 99: 14392-7.
87. Zanesi N, Aqeilan R, Drusco A, et al. Effect of Rapamycin on Mouse Chronic Lymphocytic Leukemia and the Development of Nonhematopoietic Malignancies in E{micro}-TCL1 Transgenic Mice. Cancer Res 2006; 66: 915-20.
88. Robak T. Second malignancies and Richter's syndrome in patients with chronic lymphocytic leukemia. Hematology 2004; 9: 387-400.
89. Kyasa MJ, Hazlett L, Parrish RS, Schichman SA, Zent CS. Veterans with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) have a markedly increased rate of second malignancy, which is the most common cause of death. Leuk Lymphoma 2004; 45: 507-13.
90. Yan XJ, Albesiano E, Zanesi N, et al. B cell receptors in TCL1 transgenic mice resemble those of aggressive, treatment-resistant human chronic lymphocytic leukemia. Proc Natl Acad Sci USA 2006; 103: 11713-8.
91. Enzler T, Kater AP, Zhang W, et al. Chronic lymphocytic leukemia of Emu-TCL1 transgenic mice undergoes rapid cell turnover that can be offset by extrinsic CD257 to accelerate disease progression. Blood 2009; 114: 4469-76.
92. Sanchez-Aguilera A, Rattmann I, Drew DZ, et al. Involvement of RhoH GTPase in the development of B-cell chronic lymphocytic leukemia. Leukemia 2010; 24: 97-104.
93. Scielzo C, Bertilaccio MT, Simonetti G, et al. HS1 has a central role in the trafficking and homing of leukemic B cells. Blood 2010; 116: 3537-46.
94. Suljagic M, Longo PG, Bennardo S, et al. The Syk inhibitor fostamatinib disodium (R788) inhibits tumor growth in the Emu-TCL1 transgenic mouse model of CLL by blocking antigen-dependent Bcell receptor signaling. Blood 2010; 116: 4894-905.
95. Norton JD, Deed RW, Craggs G, Sablitzky F. Id helix-loop-helix proteins in cell growth and differentiation. Trends Cell Biol 1998; 8: 58-65.
96. Carey JP, Asirvatham AJ, Galm O, Ghogomu TA, Chaudhary J. Inhibitor of differentiation 4 (Id4) is a potential tumor suppressor in prostate cancer. BMC Cancer 2009; 9: 173.
97. Yu L, Liu C, Vandeusen J, et al. Global assessment of promoter methylation in a mouse model of cancer identifies ID4 as a putative tumor-suppressor gene in human leukemia. Nat Genet 2005; 37: 265-74.
98. Chen SS, Claus R, Lucas DM, et al. Silencing of the inhibitor of DNA binding protein 4 (ID4) contributes to the pathogenesis of mouse and human CLL. Blood 2011; 117: 862-71.
99. Patten PE, Buggins AG, Richards J, et al. CD38 expression in chronic lymphocytic leukemia is regulated by the tumor microenvironment. Blood 2008; 111: 5173-81.
100. Tinhofer I, Weiss L, Gassner F, Rubenzer G, Holler C, Greil R. Difference in the relative distribution of CD4+ T-cell subsets in BCLL with mutated and unmutated immunoglobulin (Ig) VH genes: implication for the course of disease. J Immunother 2009; 32: 302-9.
101. Hofbauer JP, Heyder C, Denk U, et al. Development of CLL in the TCL1 transgenic mouse model is associated with severe skewing of the T-cell compartment homologous to human CLL. Leukemia 2011; 25: 1452-8.
102. Muzio M, Bertilaccio MT, Simonetti G, Frenquelli M, Caligaris- Cappio F. The role of toll-like receptors in chronic B-cell malignancies. Leuk Lymphoma 2009; 50: 1573-80.
103. Garlanda C, Anders HJ, Mantovani A. TIR8/SIGIRR: an IL- 1R/TLR family member with regulatory functions in inflammation and T cell polarization. Trends Immunol 2009; 30: 439-46.
104. Bertilaccio MT, Simonetti G, Dagklis A, et al. Lack of TIR8/SIGIRR triggers progression of chronic lymphocytic leukemia in mouse models. Blood 2011; 118: 660-9.
105. Frenquelli M, Muzio M, Scielzo C, et al. MicroRNA and proliferation control in chronic lymphocytic leukemia: functional relationship between miR-221/222 cluster and p27. Blood 2010; 115: 3949-59.
106. Efanov A, Zanesi N, Nazaryan N, et al. CD5+CD23+ leukemic cell populations in TCL1 transgenic mice show significantly increased proliferation and Akt phosphorylation. Leukemia 2010; 24: 970-975